These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20198329)

  • 1. Carvedilol in glioma treatment alone and with imatinib in vitro.
    Erguven M; Yazihan N; Aktas E; Sabanci A; Li CJ; Oktem G; Bilir A
    Int J Oncol; 2010 Apr; 36(4):857-66. PubMed ID: 20198329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma.
    Bilir A; Erguven M; Oktem G; Ozdemir A; Uslu A; Aktas E; Bonavida B
    Int J Oncol; 2008 Apr; 32(4):829-39. PubMed ID: 18360710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
    O'Reilly T; Wartmann M; Maira SM; Hattenberger M; Vaxelaire J; Muller M; Ferretti S; Buchdunger E; Altmann KH; McSheehy PMJ
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):307-317. PubMed ID: 15723258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro.
    Aras Y; Erguven M; Aktas E; Yazihan N; Bilir A
    Neurol Res; 2016 Sep; 38(9):766-74. PubMed ID: 27367429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells.
    Shingu T; Fujiwara K; Bögler O; Akiyama Y; Moritake K; Shinojima N; Tamada Y; Yokoyama T; Kondo S
    Int J Cancer; 2009 Mar; 124(5):1060-71. PubMed ID: 19048625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.
    Pessetto ZY; Ma Y; Hirst JJ; von Mehren M; Weir SJ; Godwin AK
    Mol Cancer Ther; 2014 Oct; 13(10):2276-87. PubMed ID: 25122069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of imatinib at different concentrations on rat C6 glioma cell apoptosis and cell cycle].
    Yang L; Xu ZY; Chen XH; Wang KW; Li GF; Chen ZL
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):1089-91. PubMed ID: 20501402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.
    Kim JH; Song M; Kang GH; Lee ER; Choi HY; Lee C; Kim JH; Kim Y; Koo BN; Cho SG
    Leuk Res; 2012 Sep; 36(9):1157-64. PubMed ID: 22770910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
    Tzadok S; Beery E; Israeli M; Uziel O; Lahav M; Fenig E; Gil-Ad I; Weizman A; Nordenberg J
    Int J Oncol; 2010 Oct; 37(4):1043-51. PubMed ID: 20811727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay.
    Kinsella P; Clynes M; Amberger-Murphy V
    J Neurooncol; 2011 Jan; 101(2):189-98. PubMed ID: 20512610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
    Declèves X; Bihorel S; Debray M; Yousif S; Camenisch G; Scherrmann JM
    Pharmacol Res; 2008 Mar; 57(3):214-22. PubMed ID: 18337118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin enhances antitumor action of sodium dichloroacetate against glioma C6.
    Kolesnik DL; Pyaskovskaya ON; Yurchenko OV; Solyanik GI
    Exp Oncol; 2019 Jun; 41(2):123-129. PubMed ID: 31262158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells.
    Erguven M; Akev N; Ozdemir A; Karabulut E; Bilir A
    Med Sci Monit; 2008 Aug; 14(8):BR165-73. PubMed ID: 18667993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib.
    Lu J; Hu Y; Qian R; Zhang Y; Yang X; Luo P
    Eur J Pharmacol; 2020 May; 874():173022. PubMed ID: 32084420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cell cycle arrest at G1 and S phases and cAMP-dependent differentiation in C6 glioma by low concentration of cycloheximide.
    Liu X; Yang JM; Zhang SS; Liu XY; Liu DX
    BMC Cancer; 2010 Dec; 10():684. PubMed ID: 21159181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics.
    Wietrzyk J; Milczarek M; Kutner A
    Oncol Res; 2007; 16(11):517-25. PubMed ID: 18306931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.